Fibrolamellar Carcinoma — Trials

Fibrolamellar Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

21 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 18%
Top sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04380545	Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer	recruiting	Phase 1 / Phase 2	15	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026	clinicaltrials
NCT06789198	Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA(FusionVAC22_02)	recruiting	Phase 1	20	University Hospital TuebingenOTHER	1	Sep 14, 2026